Doc No.

: LPL/R/QF/2711
Dr.Lal PathLabs
Rohini Sector -18, Block E, Rohini, New Delhi-110085
Phone : 011- 30244100, 011-39885050
E-mail : lalpathlabs@lalpathlabs.com; Website: www.lalpathlabs.com
CONSENT FOR HIV TESTING
Lab No:
Date:
Name: Sex: Age:
Address:
Tel.: Mobile:
Consent:
I, the undersigned agree to get my blood tested for HIV Antibodies and provide my identification proof *. The significance and
relevant information of this test (Pre Test Counseling) have been provided to me.
Result:
In understand that my result will be kept confidential and authorize the following person / agency to collect my report.
Self Ref. Doctor Ref. Agency Relative
Post Test Counseling will be given by my attending Doctor.

Signature of patient: ...........................................................

GENERAL INFORMATION ON HIV
HIV or Human Immunodeficiency Virus is the causative agent of AIDS (Acquired Immune Deficiency Syndrome). There are
two forms of HIV Virus.HIV-1 & HIV-2 .However HIV-1 is the predominant agent of HIV infection worldwide. HIV disease is
characterized by progressive immunodeficiency associated with qualitative depletion of CD4+ T cells .Advanced HIV disease
is referred to as the Acquired Immunodeficiency Syndrome or AIDS.
Modes of transmission
*Sexual contact both homosexual and heterosexual
*Contaminated blood or blood products including contaminated injection and cosmetic equipment.
*Infected mothers to infant’s intrapartum, perinatally and breast milk.
Not Transmitted by
*Kissing and hugging
*Holding Hands
*Sharing drinking or eating utensils
*Living in a house with an HIV positive person
*Toilet seats
*Mosquitoes or any other nonhuman organism.
Diagnosis
1. Demonstration of antibodies to HIV
ELISA: HIV antibodies generally appear in the circulation 4-8 weeks after infection Standard test is the ELISA test with
sensitivity of over 99.5%.This detects both HIV-1 and HIV -2 at LPL, HIV tests are performed on 2 different kits, before
reporting results.
Western Blot: Most commonly used confirmatory test.
2. Direct detection of HIV RNA (Antigen)
Measurement of HIV RNA overt time has been of great value in delineating the relationship between levels of virus and rates
of diseases progression, rates of viral replication and the time to develop and antiviral drug resistance. Measurements should
be made at approximately every 6 months and frequently in a setting of changes of antiretroviral therapy. A level of >20,000
copies/ml is an indication for antiretroviral therapy.
HIV PCR: Gold Standard for diagnosis of HIV infection in at-risk neonates. It is positive in 98% of patients detecting down to
40 copies/ml of HIV RNA. The only test that can diagnose the HIV infection in Window Period.
Window Period
This is the period form the time of initial infection to the production of HIV antibodies in the blood. It is known as
seroconversion and varies from 3-12 weeks .The gap between infection and seroconversion is termed as the window period.
During this time the infectious virus is present in the body although the results form the antibody will be negative. Hence a
retest 6 months later is recommended.
Monitoring of Therapy
CD4 & CD8 T cell percent and absolute counts: Correlate with disease progression, a fall in CD4 and a rise in CD8 counts
occur during the course of the disease.
HIV bDNA: Quantitation of the virus is another valuable method for monitoring disease progression and therapy. This test
detects down to 50 copies/ml of HIV RNA.
Incubation Period
A person may carry the HIV virus for a span of 10 years before progression to full blown AIDS. During this period the person
shows no signs and symptoms of the underlying disease but is capable of transmitting infection.

* In newborn/ children identification card of either parent is mandatory

*In adoption cases proof from orphanage/ agency is mandatory
 Doc No. : LPL/R/QF/2711
Dr.Lal PathLabs
Rohini Sector -18, Block E, Rohini, New Delhi-110085
Phone : 011- 30244100, 011-39885050
E-mail : lalpathlabs@lalpathlabs.com; Website: www.lalpathlabs.com
,p vkbZ oh HIV ijh{k.k ds fy, lgefr

ySc Øekad %
fnukad %
Ukke vk;q % fyax %
irk
VsfyQksu u% eksckbZy u%
lgefr
eSa] v/kksgLrk{kjh] vius [kwu esa ,p vkbZ oh ,aVhckWMh ds ifj{k.k ds fy, vkSj viuk igPkkui=* nsus d¢ fy, viuh lgefr iznku djrk A
eq>s bl ijh{k.k ls lEcfU/kr tkudkjh ,oa bldk egRo ¼ijh{k.k iwoZ dkmUlfyax½ crk fn;k x;k gSA
ifj.kke
eSa leÖkrk gSaw fd esjk ijh.kke xksiuh; j[kk tk,xkk vkSj eSa fuEu O;fDr vFkok ,tsalh dks esjh fjiksVZ ,d= djus ds fy, vf/kd`r djrk gSawA

Lo;a ijke’kZ fpfdRld ijke’kZ ,tsalh fj'rsnkj

ijh{k.k Ik'Pkkr dkmUlfyax esjs fpfdRld djsaxsA
ejht ds gLrk{kj ---------------------------------------------------------------------
,p vkbZ oh ij lkekU; tkudkjh
,p vkbZ oh ds ok;jl ls ,M~l gksrk gSA
,M~l dk eryc gS og fcekjh ds 'kjhj esa izfrj{kk de djds y{k.k nsrh gSA ,p vkbZ oh dk eryc gS ekuo izfrj{kk dks de djus okyk thok.kq A ,p vkbZ oh ok;jl ds
nks izdkj gksrs gSaS A ,p vkbZ oh ,oa ,p vkbZ oh 2 iwjs fo’o esa ,p vkbZ oh 1 ,p vkbZ oh ds laØe.k dk izeq[ k dkj.k gSA ,p vkbZ oh jksx esa 'kjhj dh izfrj{kk ,oa lh Mh 4
(+) Vh lSYl (CD4 Positive T cells) de gksrs tkrs gSaA ,p vkbZ oh jksx dh c<h gqbZ voLFkk dks ,M~l vDok;MZ (Acquired) bequks (Immuno) MsfQfl,alh
(Deficiency) flMªkase (Syndrome) dgrs gSA
laØe.k ds izdkj ¼vf/kdk'ka yksxksa dks fuEu izdkj ls ,M~l feyrk gS½ %
 lØafer O;fDr ls vlqjf{kr ;kSu lEcU/k ls ;k lsDl ls leySafxdrk ,oa fo"keySfxd
 lØafer [kwu izkIr djus ls] lØafer O;fDr ds lqbZ ysus ,oa lØafer lkSan;Z midj.kksa lsA
 lØafer ek¡ ds cPps dks ,oa lØafer ek¡ ds nw/k ls
buls laØe.k ugha QSyrk gS%
 xky ij pqEcu yus ,oa xys feyus lsA
 gkFk idMus ls
 [kkus o ihus ds crZuksa dh lk>snkjh ls
 ,p vkbZ oh O;fDr ds ?kj esa jgus ls
 'kkSpky; dh lhV ls
 ePNj] canj vkSj vU; dksbZ tho tks euq"; u gksA
tk¡p ¼ijh{k.k½
,p vkbZ oh ,aVhckWMh dk izek.k
,yvkbZtk % vkerkSj ij laØe.k ds 4&8 lIrkg ckn ,pvkbZoh ,aVhckWMh ijhlapj.k esa izdV gksrs gSaA ,yvkbZtk ,d izekf.kd ijh{k.k gS ftldh lw{exzfgrk 99-5% ls vf/kd
gSA ;g ,pvkbZoh 1 ,oa ,pvkbZoh 2 nksuks dk irk yxrk gSA ,yih,y esa ,pvkbZoh ijh{k.k ikthfVWo vkus ij ifj.kke crkus iwoZ nks fHkUu fdV~l ls nksckjk
ijh{k.k fd;k tkrk gSA
oS’VuZ CykV % lkekU;r% ;g ijh{k.k iw.kZ :i ls fuf'pr djus ds fy, fd;k tkrk gSA
1- ,pvkbZoh vkj ,u , ¼,Vhatu½ dh lh/kh tk¡p jksx dh izxfr ,oa ok;jl ds ysoy ds lEcU/k] izfrjks/kd {kerk ,oa ok;jl dh izxfr ds chp ds lEcU/k ,oa
,aVhok;jy vkS"kf/k ds izfrjks/k cuus dk le; dks le>us ds fy, ,pvkbZoh vkj ,u , dh eki cgqr egRo j[krh gSA bldh eki Ng eghus ds varjky ij djkuk
pkfg,] mipkj ifjorZu dh voLFkk esa vkSj Hkh de varjky ij djkbZ tkuh Pkkfg,A
2- ;g uotkr f'k'kq esa ,p vkbZ oh lØae.k irk djus dk Lo.kZ ekud gSA ;g ifj{k.k 98% ejhtksa esa 40 copies /mL dks [kkst ysrk gSA ;g vdsyk ifj{k.k gS
tks ,p vkbZ oh dks foaMks ihfj;M esa ijh{k.k djrk gSA
foUMks ihfj;M (Window Period)
laØe.k gksus ls ,aVhckWMh cuus ds chp ds le; dks fouMks ihfj;M dgrs gSA bls lhjksdUoZtu (Seroconversion) dgrs gSA bles rhu ls ckjg lIrkg yxrs gSA laØe.k
vkSj lhjksdUotZu ds chp ds le; dks fouMks ihfj;M dgrs gSA bl le; vrajky esa loafer ok;jl 'kjhj esa gksrk gSA ysfdu ,afVckWMh VsLV dk ifj.kke usxsfVo vkrk gSA
blfy, N% efgus ckn iqu% ifj{k.k djkus dk ijke’kZ fn;k tkrk gSA
mipkj dks fuxjkuh
lh Mh 4 ,oa lh Mh 8 T cell ,oa fujis{k l[a;k % ;g jksx c<us ls ijLij lEcU/k j[krh gS] jksx c<us ij lh Mh 4 dkamV de ,oa lh Mh 8 dkmaV c<rh gSA
,p vkbZ oh Mh ,u , (HIV DNA)5: jksx ds c<us ,oa mipkj dh fuxjkuh dk ok;jl dh fxurh djokuk nwljk egRoiw.kZ rjhdk gSA
;g ifj{k.k 50 copies / mL rd dks [kkst ysrk gSA
Å"ek;u vof/k (Incubation Period)
,p vkbZ oh ok;jl laØe.k ls iwjh rjg ls ,M~l gksus esa 10 o"kZ rd dk le; yx ldrk gSA bl le; esa ejht dks dksbZ Hkh y{k.k ;k ladsr uagh fn[kkbZ nsrk ysfdu og
nwljs O;fDr;ksa dks laØfer dj ldrk gSA
*uotkr f'k'kq ,oa CkPp®a dh fLFkfr esa ekrk ¸kk firk dk igPkkui= vfuOkk¸kZ gSA
*Xk®n ysus dh fLFkfr esa vukFkky¸k@laLFkk ls çek.ki= vfuOkk¸kZ gSA